Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Inks Comarketing Pacts With Ultivue, ImaBiotech

NEW YORK – Fluidigm on Thursday said it has entered into a pair of comarketing agreements related to its Imaging Mass Cytometry technology platform.

Under a comarketing agreement with Ultivue, the companies will collaborate to offer a comprehensive portfolio of solutions for biomarker discovery and drug development. Cambridge, Massachusetts-based Ultivue uses its InSituPlex technology to develop assays for use in multiplex immunofluorescence imaging and analysis.

Fluidigm's IMC technology, meanwhile, is designed for highly multiplexed, targeted interrogation of tissue sections for 40 or more protein markers per scan. Combining the two platforms provides researchers with an end-to-end service for clinical and translational research, the companies said.

Fluidigm also inked a collaboration and comarketing agreement with ImaBiotech, a contract research organization that offers spatial multiomics services to pharmaceutical researchers with an emphasis on precision medicine approaches to evaluating drug efficacy and toxicity.

ImaBiotech will use Fluidigm's Hyperion Imaging System to offer mass cytometry as one of its core technologies out of its GLP research facilities in the US and Europe.

"Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs," ImaBiotech CEO Jonathan Stauber said in a statement. "We are excited for the opportunity to collaborate with Fluidigm in this regard, innovating applications and products, including new panel development, to make Imaging Mass Cytometry an even more powerful tool."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.